Literature DB >> 27882414

Systemic endothelial function measured by flow-mediated dilation is impaired in patients with urolithiasis.

Esin Yencilek1, Hakan Sarı2, Faruk Yencilek3, Ezgi Yeşil4, Hasan Aydın5,6.   

Abstract

Some in vitro and animal studies have shown endothelial dysfunction in hyperoxaluria models indicating its role in pathogenesis of urolithiasis and relation to CVD. The aim of this study was to investigate endothelial function in patients with urolithiasis in relation to urinary stone risk factors and metabolic parameters. A total of 120 subjects without any known CVD (60 with urolithiasis and 60 healthy subjects) were included into study. Fasting blood and 24-h urine samples were collected to study metabolic parameters (glucose and lipids) and urine stone risk factors (oxalate, citrate, uric acid, and calcium, pH). Endothelial function was assessed as flow-mediated dilation (FMD) at the brachial artery. Age, sex, and body mass index were similar in patients and controls. Of urine stone risk factors, oxalate and citrate were higher in patients than controls. Fasting blood glucose, total LDL cholesterol, and triglyceride were higher, and HDL cholesterol was lower in patients than controls. Although within normal limits systolic blood pressure was higher in patient group, patients with urolithiasis had a lower %FMD than controls. Percent FMD was negatively correlated with urinary oxalate/creatinine ratio (p = 0.019, r = -0.315), calcium/creatinine ratio (p = 0.0001, r = -0.505) age (p < 0.001, r = -0.694), BMI (p < 0.001, r = -0.838), total cholesterol (p < 0.001, r = -0.559), and triglyceride (p < 0.001, r = -0.529). Urine oxalate/creatinine ratio was positively correlated with age (p = 0.01, r = 0.327) and calcium/creatinine ratio with BMI (p = 0.001, r = 0.410). This is the first study demonstrating endothelial dysfunction in human subjects with urolithiasis. This indicates a possible predictive role of urolithiasis in future development of cardiovascular diseases.

Entities:  

Keywords:  Cardiovascular risk; Endothelial dysfunction; Flow-mediated dilation; Urolithiasis

Mesh:

Substances:

Year:  2016        PMID: 27882414     DOI: 10.1007/s00240-016-0941-2

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  38 in total

Review 1.  Endothelial function and dysfunction: testing and clinical relevance.

Authors:  John E Deanfield; Julian P Halcox; Ton J Rabelink
Journal:  Circulation       Date:  2007-03-13       Impact factor: 29.690

Review 2.  Assessment of risk for developing coronary heart disease in asymptomatic individuals.

Authors:  C Tissa Kappagoda; E A Amsterdam
Journal:  J Cardiopulm Rehabil Prev       Date:  2009 Jul-Aug       Impact factor: 2.081

3.  Increased 10-year cardiovascular disease and mortality risk scores in asymptomatic patients with calcium oxalate urolithiasis.

Authors:  Hasan Aydin; Faruk Yencilek; Ismet Bilger Erihan; Binnur Okan; Kemal Sarica
Journal:  Urol Res       Date:  2011-05-13

Review 4.  Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome?

Authors:  Saeed R Khan
Journal:  Urol Res       Date:  2012-01-04

Review 5.  Inhibitors of calcification in blood and urine.

Authors:  Georg Schlieper; Ralf Westenfeld; Vincent Brandenburg; Markus Ketteler
Journal:  Semin Dial       Date:  2007 Mar-Apr       Impact factor: 3.455

6.  Postprandial hyperinsulinaemia, insulin resistance and inappropriately high phosphaturia are features of younger males with idiopathic calcium urolithiasis: attenuation by ascorbic acid supplementation of a test meal.

Authors:  P O Schwille; A Schmiedl; U Herrmann; J Wipplinger
Journal:  Urol Res       Date:  1997

Review 7.  Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction.

Authors:  Thomas Münzel; Christoph Sinning; Felix Post; Ascan Warnholtz; Eberhard Schulz
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

8.  Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction.

Authors:  D S Celermajer; K E Sorensen; C Bull; J Robinson; J E Deanfield
Journal:  J Am Coll Cardiol       Date:  1994-11-15       Impact factor: 24.094

9.  Urinary IL-6 is elevated in patients with urolithiasis.

Authors:  E Rhee; L Santiago; E Park; P Lad; G C Bellman
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

10.  The Risk of Coronary Heart Disease in Patients with Kidney Stones: A Systematic Review and Meta-analysis.

Authors:  Wisit Cheungpasitporn; Charat Thongprayoon; Michael A Mao; Oisin A O'Corragain; Peter J Edmonds; Stephen B Erickson
Journal:  N Am J Med Sci       Date:  2014-11
View more
  5 in total

1.  Hyperoxaluria Induces Endothelial Dysfunction in Preglomerular Arteries: Involvement of Oxidative Stress.

Authors:  Javier Saenz-Medina; Mercedes Muñoz; Claudia Rodriguez; Cristina Contreras; Ana Sánchez; María José Coronado; Elvira Ramil; Martin Santos; Joaquín Carballido; Dolores Prieto
Journal:  Cells       Date:  2022-07-27       Impact factor: 7.666

Review 2.  Nephrolithiasis: A Red Flag for Cardiovascular Risk.

Authors:  Alessia Gambaro; Gianmarco Lombardi; Chiara Caletti; Flavio Luciano Ribichini; Pietro Manuel Ferraro; Giovanni Gambaro
Journal:  J Clin Med       Date:  2022-09-20       Impact factor: 4.964

3.  Urolithiasis Develops Endothelial Dysfunction as a Clinical Feature.

Authors:  Javier Sáenz-Medina; María Martinez; Silvia Rosado; Manuel Durán; Dolores Prieto; Joaquín Carballido
Journal:  Antioxidants (Basel)       Date:  2021-05-04

4.  Elevated non-high-density lipoprotein cholesterol corresponds to a high risk of nephrolithiasis in children.

Authors:  Meiyuan Chen; Jing Xiao; Yuan Du; Miaomiao Wang; Jimeng Ruan; Ye Tian
Journal:  BMC Urol       Date:  2020-08-10       Impact factor: 2.264

Review 5.  Endothelial Dysfunction: An Intermediate Clinical Feature between Urolithiasis and Cardiovascular Diseases.

Authors:  Javier Saenz-Medina; Mercedes Muñoz; Claudia Rodriguez; Ana Sanchez; Cristina Contreras; Joaquín Carballido-Rodríguez; Dolores Prieto
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.